MDK-4204

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 526394

CAS#: 1983924-20-4

Description: MDK-4204, also known as Anticancer Agent-I, is a novel anticancer agent, showing most significant anti-cancer activity against prostate cancer cells with IC50 values of 8.8 µM and 9.5 µM in PC-3 and DU-145 cells, respectively. MDK-4204 has CAS#1983924-20-4. The last 4 digital of CAS# is used in its name.


Chemical Structure

img
MDK-4204
CAS# 1983924-20-4

Theoretical Analysis

MedKoo Cat#: 526394
Name: MDK-4204
CAS#: 1983924-20-4
Chemical Formula: C31H29FN4O
Exact Mass: 492.23
Molecular Weight: 492.598
Elemental Analysis: C, 75.59; H, 5.93; F, 3.86; N, 11.37; O, 3.25

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: MDK-4204; MDK 4204; MDK4204; Anticancer AgentI; Anticancer Agent I; Anticancer Agent-I

IUPAC/Chemical Name: (3E,5E)-1-[[1-[(2-Fluorophenyl)methyl]-1H-1,2,3-triazol-4-yl]methyl]-3,5-bis[(4-methylphenyl)methylene]-4-piperidinone

InChi Key: YHWZDCHFTZTNIV-DPCVLPDWSA-N

InChi Code: InChI=1S/C31H29FN4O/c1-22-7-11-24(12-8-22)15-27-17-35(18-28(31(27)37)16-25-13-9-23(2)10-14-25)20-29-21-36(34-33-29)19-26-5-3-4-6-30(26)32/h3-16,21H,17-20H2,1-2H3/b27-15+,28-16+

SMILES Code: O=C1/C(CN(CC2=CN(CC3=CC=CC=C3F)N=N2)C/C1=C\C4=CC=C(C)C=C4)=C/C5=CC=C(C)C=C5

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 492.60 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Miyake H, Imai S, Tamura K, Sugiyama T, Furuse H, Ozono S, Fujisawa M. Comparison of Tyrosine Kinase Inhibitor Versus Mammalian Target of Rapamycin Inhibitor as Second-line Molecular-targeted Therapy for Patients with Poor-risk Metastatic Renal Cell Carcinoma. Anticancer Res. 2017 Mar;37(3):1523-1528. PubMed PMID: 28314328.

2: Arvanitis CD, Bazan-Peregrino M, Rifai B, Seymour LW, Coussios CC. Cavitation-enhanced extravasation for drug delivery. Ultrasound Med Biol. 2011 Nov;37(11):1838-52. doi: 10.1016/j.ultrasmedbio.2011.08.004. Epub 2011 Oct 2. PubMed PMID: 21963037.

3: Beck R, Dejeans N, Glorieux C, Pedrosa RC, Vásquez D, Valderrama JA, Calderon PB, Verrax J. Molecular chaperone Hsp90 as a target for oxidant-based anticancer therapies. Curr Med Chem. 2011;18(18):2816-25. Review. PubMed PMID: 21568884.

4: Ahn S, Kearbey JD, Li CM, Duke CB 3rd, Miller DD, Dalton JT. Biotransformation of a novel antimitotic agent, I-387, by mouse, rat, dog, monkey, and human liver microsomes and in vivo pharmacokinetics in mice. Drug Metab Dispos. 2011 Apr;39(4):636-43. doi: 10.1124/dmd.110.036673. Epub 2011 Jan 13. PubMed PMID: 21233217.

5: Marx G, Zhou H, Graves DE, Osheroff N. Covalent attachment of ethidium to DNA results in enhanced topoisomerase II-mediated DNA cleavage. Biochemistry. 1997 Dec 16;36(50):15884-91. PubMed PMID: 9398321.